Ipsen

Ipsen SA engages in the research, development, manufacture, and sale of pharmaceutical products worldwide.

Launch date

1929

Employees

5001-10000 people

Market cap

Enterprise valuation

CAD12.7b (Public information from Sep 2024)

Boulogne-Billancourt Île-de-France (HQ)

http://ipsen.com

https://twitter.com/ipsengroupfr https://www.facebook.com/ipsengroup https://www.linkedin.com/company/ipsen/https://apps.apple.com/app/id1299421717 https://play.google.com/store/apps/details?id=com.reyelise.IPSEN2019

Revenues, earnings & profits over time

EUR	2020	2021	2022	2023	2024	2025	2026
Revenues	2.7b	2.7b	3.2b	3.3b	3.5b	3.7b	4.0b
% growth	-	2 %	15 %	5 %	5 %	7 %	7 %
EBITDA	958m	1.1b	1.2b	643m	1.2b	1.3b	1.3b
% EBITDA margin	36 %	40 %	38 %	19 %	34 %	34 %	34 %
Profit	548m	647m	649m	644m	592m	706m	784m
% profit margin	20 %	24 %	21 %	19 %	17 %	19 %	20 %
EV / revenue	2.3x	2.5x	2.5x	2.7x	2.5x	2.2x	1.9x
EV / EBITDA	6.4x	6.2x	6.5x	13.8x	7.2x	6.3x	5.4x
R&D budget	406m	424m	445m	619m	-	-	-
R&D % of revenue	15 %	15 %	14 %	19 %	-	-	-

Source: Dealroom estimates

Date	Investors	Amount	Round
Dec 2005	N/A	N/A	IPO
Nov 2017	N/A	£22.0m	Post IPO Equity
Total Funding		-

Tech stackLearn more about the technologies and tools that this company uses.

By Country

United States 9 Canada 1 France 1 United Kingdom 1 Germany 1

By Industry

Health 13 Enterprise Software 1

By Round

ACQUISITION 7 SERIES B 3 SERIES A 3 LATE VC 2 SERIES C 1

Thesan Pharmaceuticals

ACQUISITION by Ipsen Jan 2023

Clementia Pharmaceuticals

ACQUISITION by Ipsen Feb 2019

ACQUISITION by Ipsen Jun 2008

ACQUISITION by Ipsen Jun 2022

Rhythm Pharmaceuticals

exited

ACQUISITION by Ipsen Jul 2013

Canbex Therapeutics

ACQUISITION by Ipsen Feb 2015

OctreoPharm Sciences

ACQUISITION by Ipsen Jun 2015